Related references
Note: Only part of the references are listed.Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
Andrius Zucenka et al.
ANNALS OF HEMATOLOGY (2021)
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
Maansi Joshi et al.
BLOOD CANCER JOURNAL (2021)
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation
Andrius Zucenka et al.
BONE MARROW TRANSPLANTATION (2021)
Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation
Iman Abou Dalle et al.
BONE MARROW TRANSPLANTATION (2021)
Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success
Ilaria M. Michelozzi et al.
CANCERS (2021)
How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ali Bazarbachi et al.
HAEMATOLOGICA (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT
Olaf Penack et al.
BLOOD ADVANCES (2020)
Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Ahmad Antar et al.
FRONTIERS IN ONCOLOGY (2020)
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Catherine J. Lee et al.
BONE MARROW TRANSPLANTATION (2019)
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party
Ali Bazarbachi et al.
HAEMATOLOGICA (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
Simona Piemontese et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort
Henry Wood et al.
BLOOD (2019)
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Avichai Shimoni et al.
BLOOD CANCER JOURNAL (2019)
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation
Robert Zeiser et al.
BLOOD (2019)
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy
Naval G. Daver et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation
Max Jan et al.
BLOOD ADVANCES (2019)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
Christoph Schmid et al.
HAEMATOLOGICA (2018)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
Christoph Schmid et al.
HAEMATOLOGICA (2018)
Epidemiology and biology of relapse after stem cell transplantation
Mary Horowitz et al.
BONE MARROW TRANSPLANTATION (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia
C. Craddock et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver et al.
LEUKEMIA (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja et al.
JAMA ONCOLOGY (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Thomas Schroeder et al.
ANNALS OF HEMATOLOGY (2018)
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Iman Abou Dalle et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
S. K. Metzelder et al.
EUROPEAN JOURNAL OF CANCER (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia
Giorgia Battipaglia et al.
CANCER (2017)
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant
Ibraheem H. Motabi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Marlise R. Luskin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea et al.
BLOOD (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
Akiyoshi Takami et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation
Amer M. Zeidan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation
Mariana Bastos-Oreiro et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia
Raynier Devillier et al.
LEUKEMIA & LYMPHOMA (2013)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon et al.
CANCER CELL (2011)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
Xiangli Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine
Thorsten Graef et al.
LEUKEMIA RESEARCH (2007)
Share Paper
